Quantcast
Last updated on April 16, 2014 at 12:14 EDT

Latest Drug Development Stories

2014-04-16 09:48:04

Over 20 years after the fatal fialuridine trial, a study published this week in PLOS Medicine demonstrates that mice with humanized livers recapitulate the drug's toxicity. The work suggests that this mouse model should be added to the repertoire of tools used in preclinical screening of drugs for liver toxicity before they are given to human participants in clinical trials. A retrospective analysis by the US National Academy of Sciences of all preclinical fialuridine toxicity tests, which...

2014-04-15 12:30:12

Two-part webinar to highlight benefits of molecular imaging in drug development MATTAWAN, Mich., April 15, 2014 /PRNewswire/ -- MPI Research and Translational Imaging Center partners, inviCRO, and 3D Imaging, announce a complementary two-part webinar series that will examine the game-changing benefits of translational research approaches utilizing molecular imaging. Part I of the series, Bridging the Gap with Translational Imaging: Drug Development from Mouse to Man, kicks off on...

2014-04-15 08:30:06

Purchase adds global regulatory writing and submission services to Certara's drug development consulting expertise NEW YORK, April 15, 2014 /PRNewswire/ -- Arsenal Capital Partners, a leading New York based private equity firm that invests in middle market healthcare, specialty industrial, and financial services companies, announced today the acquisition of Synchrogenix, the leading regulatory writing and related services firm. Synchrogenix provides services to pharmaceutical,...

2014-04-11 08:24:59

LAS VEGAS, April 11, 2014 /PRNewswire/ -- The International Society for CNS Drug Development (ISCDD) has announced that Dr. John H. Greist was the recipient of the 2014 ISCDD Award at its 12th Annual Meeting. The 2014 ISCDD Award was presented to Dr. Greist by Dr. Bill Potter, the current Chairman of the ISCDD Executive Committee, and Dr. George Garibaldi, the Chairman-Elect. Dr. Potter and Dr. Garibaldi discussed Dr. Griest's long career and commented that it was very appropriate...

2014-04-10 23:22:55

Novel Approach May Help to Prevent False Positive Cardiac Safety Findings in New Drug Development Philadelphia (PRWEB) April 10, 2014 ERT, a leading global solution provider for high-quality patient safety and efficacy endpoint data collection, today announced it has entered into an agreement with GE Healthcare that enables ERT to introduce the QT Guard Plus Analysis System to the clinical trial industry as part of its centralized cardiac safety solutions. The QT Guard Plus Analysis...

2014-04-04 23:33:41

MPI’s Drug Response Predictor (DRP) can generate new and unique clinically relevant gene signatures - a strong complementary drug development tool; TD2 is an oncology drug development company that customizes clinical trial design and execution for its customers by applying rigorous and high-throughput translational preclinical development, with best in class regulatory and clinical expertise. Scottsdale, Ariz., USA and Hoersholm, Denmark (PRWEB) April 03, 2014 Medical Prognosis...

2014-04-02 16:31:56

SAN DIEGO, April 2, 2014 /PRNewswire/ -- Polaris Group announced today that Shaw T. Chen, M.D., Ph.D. has joined Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group) as Executive Vice-President of Regulatory Affairs. Dr. Chen had previously been with the United States (US) Food & Drug Administration (FDA) for over 26 years in new drug development as a primary/supervisory medical staff. His achievements at the FDA included management of new drug review divisions, drafting...

2014-04-02 04:21:07

LAUSANNE, Switzerland and HAMBURG, Germany, April 2, 2014 /PRNewswire/ -- - Innovative partnership based on Evotec's Target X projects - Evotec and Debiopharm to share discovery and development efforts Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today a research collaboration and licensing deal with Debiopharm Group(TM), Lausanne, Switzerland. The objective of this collaboration is to identify and...

2014-04-01 23:23:16

Professionals from across East Asia will discuss the latest hot topics in all stages of drug development at the 8th DIA Annual Conference in Japan for Asian New Drug Development. Tokyo, Japan (PRWEB) April 01, 2014 Professionals from across East Asia will discuss the latest hot topics in all stages of drug development at the 8th DIA Annual Conference in Japan for Asian New Drug Development. The event will return for its eighth year on May 22 to 23, at Sola City Hall, Ochanomizu in Tokyo....

2014-04-01 08:28:09

-- Conference Focuses on New Drug Development and Cutting Edge Research in Schizophrenia -- SEATTLE, April 1, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the company was invited by the organizers of the 2014 Biennial Conference of the Schizophrenia International Research Society (SIRS) to make an oral presentation on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease....